Journal of International Psychiatry

Objective: To investigate the clinical efficacy of oxycodone sustained-release tablets alone or in combination with fluvoxamine in the treatment of moderate and severe cancer pain with depression. Methods: 102 patients with moderate or severe cancer pain and depression were divided into control group and observation group according to random number table method. 51 patients in control group and observation group were treated with oxycodone sustained-release tablets alone and oxycodone sustained-release tablets combined with fluvoxamine respectively. The degree of pain, depression and improvement of quality of life were observed in the two groups. The adverse drug reactions of the two groups were observed. Result: Before treatment, the scores of pain degree, depression state and quality of life in the two groups were higher, and there was no significant difference (P > 0.05). At 2 and 4 weeks of treatment, the scores of pain degree, depression state and quality of life in the observation group were gradually reduced, and compared with the control group at the same time, the difference was significant (P < 0.05). 23.53% of Yingzhong constipation was significantly lower than 49.02% of the control group, while 35.29% of nausea and vomiting was significantly higher than 17.65% of the control group, P < 0.05. CONCLUSION: Oxycodone sustained-release tablets combined with fluvoxamine in the treatment of moderate and severe cancer pain with depression can significantly reduce the degree of pain, and rapidly improve the state of depression and quality of life, and increase the drug will not increase the incidence of adverse reactions, with good efficacy, high safety advantages, which is worth promoting.

oxycodone sustained-release tablets; fluvoxamine; moderate and severe cancer pain; depression; adverse reactions;